FDA Febuxostat Review Could Boost Savient Gout Agent
Executive Summary
FDA's convening of a November advisory committee on Takeda North America's febuxostat for treatment-failure gout may give a boost to Savient's Puricase, which could be used as an induction agent and may get its own panel review
You may also be interested in...
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?
Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?
Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting
Savient: Still No Partner For Gout Drug
‘Don’t make promises you can’t keep,’ stockholders tell market-whipped company.